IW-1701 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Dec 22, 2017 → Jul 22, 2020
NCT ID
NCT03285178About IW-1701 + Placebo
IW-1701 + Placebo is a phase 2 stage product being developed by Cyclerion Therapeutics for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03285178. Target conditions include Sickle Cell Disease.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03285178 | Phase 2 | Completed |
| NCT02792998 | Phase 1 | Completed |
Competing Products
20 competing products in Sickle Cell Disease